Bio-identical Hormone & Peptide Specialists

Table of Contents
Cardio Res-Q Assessment from $775

Advanced labs, the Cleveland Heart panel and Dr. Varano’s evaluation:

LDL Cholesterol Levels by Risk Category: What Your Goal Should Be

LDL Cholesterol Levels by Risk Category: What Your Goal Should Be

There is no single healthy LDL cholesterol number. The right goal depends on how likely you are to have a heart attack or stroke: the higher your risk, the lower the goal.

Under the 2026 US guideline, the goals are below 100 mg/dL for people at borderline or intermediate risk, below 70 mg/dL for people at high risk, and below 55 mg/dL for people with established cardiovascular disease at very high risk. The table below sets them out.

Key takeaways

  • LDL cholesterol goals are tied to risk category, so the same result can be fine for one person and too high for another.
  • The current US goals step down from 100 to 70 to 55 mg/dL as risk rises.
  • An LDL cholesterol of 190 mg/dL or higher points to a possible inherited cause and deserves its own evaluation.
  • You need to know your risk category before an LDL result can be judged.

LDL cholesterol goals by risk category

Risk categoryLDL cholesterol goalExpected LDL reduction on treatment
Borderline or intermediate 10-year risk (3% to under 10%)Below 100 mg/dL30% to 49%
High 10-year risk (10% or more)Below 70 mg/dLAt least 50%
Established cardiovascular disease, not very high riskBelow 70 mg/dLSet with your clinician
Established cardiovascular disease, very high riskBelow 55 mg/dLSet with your clinician

In primary prevention, the 2026 ACC/AHA guideline sets an LDL cholesterol goal below 100 mg/dL for adults at borderline or intermediate 10-year risk and below 70 mg/dL for those at high risk.12

For people who already have cardiovascular disease and are at very high risk, the recommended LDL cholesterol goal is below 55 mg/dL.12

Two notes on reading the table. First, these are goals for people in whom treatment is being considered or used. They do not mean everyone with an LDL cholesterol of 105 needs medication. Second, the percentage reduction counts as well as the final number, because it reflects how much your exposure has fallen from where you started.

Where low risk fits

If your 10-year risk is below 3%, you are in the low category and the usual emphasis is on lifestyle. The picture is changing for younger adults, though. The 2026 guideline asks clinicians to look at 30-year risk as well, and to consider treatment for adults aged 30 to 59 whose 30-year risk is 10% or more even when their 10-year risk is low.3

The reasoning is that damage from LDL builds up over time. A European consensus panel concluded that risk depends on both how high LDL cholesterol is and how many years the arteries are exposed to it.4

Why goals came back

If you were told a few years ago that there were no LDL targets, that was accurate at the time. The 2013 and 2018 US guidelines emphasized the intensity of statin treatment and the expected percentage drop, not a number to reach.2

The 2026 guideline keeps those elements and adds absolute goals matched to risk. A goal gives you and your clinician something concrete to check at follow-up.

European guidelines use a similar ladder: below 116 mg/dL at low risk, below 100 at moderate risk, below 70 at high risk and below 55 at very high risk.2 The two systems now largely agree on the numbers. They differ mainly in how they sort people into categories.

When LDL is 190 mg/dL or higher

An LDL cholesterol at this level is handled differently. It can reflect an inherited tendency to high cholesterol, and it carries a long-term risk that a single 10-year estimate may not convey.

In an analysis of US cohort data, adults with LDL cholesterol of 190 mg/dL or more had up to five times the 30-year risk of coronary heart disease, with disease appearing 10 to 20 years earlier in men and 20 to 30 years earlier in women.5

If your LDL is in this range, ask about inherited causes and about testing close relatives. See signs of familial hypercholesterolemia.

Why lower goals for higher risk

The goals rest on a consistent finding: the more LDL cholesterol falls, the more events are prevented. In a meta-analysis of 26 trials with about 170,000 participants, each 1 mmol/L reduction in LDL cholesterol, roughly 39 mg/dL, cut major vascular events by 22%.6

The benefit was seen across all types of patient, including those who started with low LDL cholesterol. A fixed percentage benefit prevents more events in someone at high risk than in someone at low risk. That is why the goals tighten as risk goes up. Our article on how low LDL should go looks at the evidence and safety of very low levels.

Most treated people are not at goal

Being on medication does not mean the goal has been reached. In a national US analysis, 79% of adults taking lipid-lowering therapy for a strong guideline indication had LDL cholesterol above their 2026 goal.3

If you take a statin, it is reasonable to ask which category you are in and whether your latest result meets the goal for it. Do not change a dose or stop a medication on your own. That conversation belongs with your prescriber.

What LDL cholesterol can miss

LDL cholesterol is usually calculated, and it measures the cholesterol inside particles, not the number of particles. The 2026 guideline pairs each LDL goal with a non-HDL cholesterol goal and advises selective use of ApoB when LDL may not tell the full story. Our ApoB levels chart gives the matching numbers.

LDL is high: what now?

One high result is a starting point, not a diagnosis. These are the usual next steps. At 190 mg/dL or higher, the section above comes first.

  • Confirm the number. If the result surprises you, ask your clinician whether to repeat the test before drawing conclusions.
  • Estimate your risk. The 2026 US guideline uses the PREVENT equations to sort adults into low, borderline, intermediate and high 10-year risk.1
  • Look for risk enhancers. Early heart disease in a close relative, an ApoB of 130 mg/dL or higher and an Lp(a) of 50 mg/dL or 125 nmol/L or higher are all treated as risk enhancers.7 The 2026 guideline advises measuring Lp(a) once in every adult.1
  • Consider a calcium score if the decision is still unclear. A score of zero can support holding off on medication and rescanning in three to seven years, unless you have diabetes, smoke, have familial hypercholesterolemia or have a strong family history.18 The US Preventive Services Task Force has found the evidence insufficient to recommend calcium scoring routinely for adults without symptoms.9
  • Change what you can. Food, weight and activity all affect LDL. See how to lower LDL naturally.
  • Discuss medication when your risk calls for it. Statins are the usual first option. If a statin does not suit you, our guide to statin alternatives covers the other drug classes. Do not start, stop or change a medication without your prescriber.

Finding your risk category with Cardio Res-Q

An LDL goal is only as good as the risk estimate behind it. A Cardio Res-Q assessment gathers the inputs that refine that estimate: ApoB, Lp(a), hs-CRP, insulin, glucose and A1c, with a clinical evaluation by Dr. Varano. The Comprehensive Assessment is $775. The Enhanced Assessment is $999 and adds a CIMT ultrasound and a coronary calcium score. Calcium scoring can move people between categories, and the 2026 guideline supports an LDL goal below 55 mg/dL when the score is 1,000 or higher.2

Compare the two options in Comprehensive vs Enhanced Assessment, or go to the Cardio Res-Q program page to book.

Cardiovascular Risk Screener

Are You a Candidate for Cardio Res-Q?

Three quick questions about the risk factors we screen for. Your answers stay between you and the clinic.

Frequently asked questions

Is an LDL of 100 mg/dL normal?

It is a common result, and for someone at low risk it may need no action. For someone at high risk or with established heart disease it is above the guideline goal. The number cannot be judged without knowing your risk category.

Is an LDL of 130 mg/dL high?

It is above every treatment goal in the current US guideline, but whether it calls for medication depends on your overall risk. For a low-risk adult the first step is usually lifestyle and a look at longer-term risk.

How do I find out which risk category I am in?

Your clinician estimates your 10-year risk with a calculator, then adjusts for factors the calculator leaves out, such as family history, Lp(a) and calcium score. Our guide to the PREVENT calculator explains the first step.

I am on a statin and my LDL is 85 mg/dL. Is that enough?

It depends on your category. That result meets the goal for borderline or intermediate risk but not for high risk or established disease. Ask your prescriber, and do not adjust your medication yourself.

Related reading

This article is for general education and is not medical advice. Decisions about testing and medication should be made with your clinician. If you have chest pain or other symptoms of a heart attack, call 911.

Optimize Your Health Today!

Cardio Res-Q starts with the $775 Comprehensive or $999 Enhanced Assessment, led by Dr. Varano.

age management doctor philadelphia
Send Us A Message
About Dr. Kenneth Varano, D.O.
age management doctor philadelphia

YoungerMeMD is a physician-led practice in Anti-Aging, Functional and Preventive Medicine, and your care is delivered by our whole clinical team. That team works under Medical Director Kenneth Varano, D.O., who brings over 30 years in clinical medicine and more than 20 years in age management and functional medicine — using science-backed, patient-focused strategies that restore balance, vitality, and health longevity.

About Barbara Dougherty
anti aging treatments

Barbara Dougherty, MSN, CRNP, is a Board-Certified Family Nurse Practitioner and Certified Menopause Practitioner (MSCP) specializing in optimizing hormones, and improving cardio-metabolic health. 

Read Our Reviews

“I’ve been seeing Dr. Varano for just over a year now, and I don’t think I’ve been this healthy and energetic since grade school.

Transform Your Health Today

Ready to take the first step toward renewed energy, balance, and longevity? New patients can register for an initial evaluation to begin their personalized anti-aging journey with YoungerMe MD. Live Younger. Better. Longer. — with YoungerMe MD.

References

  1. Blumenthal RS, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2026. PMID 41824552 · doi:10.1161/CIR.0000000000001423↩
  2. Sabouret P, et al. The 2026 ACC/AHA Dyslipidemia Guideline: A Critical and Transatlantic Perspective on Personalized Lipid Management. Life (Basel) 2026. PMID 42795336 · doi:10.3390/life16091470↩
  3. Sayed A, et al. Implications of the 2026 Versus 2018 ACC/AHA Multisociety Dyslipidemia Guidelines on the Clinical Care of U.S. Adults. J Am Coll Cardiol 2026. PMID 42584382 · doi:10.1016/j.jacc.2026.06.037↩
  4. Ference BA, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017. PMID 28444290 · doi:10.1093/eurheartj/ehx144↩
  5. Perak AM, et al. Long-Term Risk of Atherosclerotic Cardiovascular Disease in US Adults With the Familial Hypercholesterolemia Phenotype. Circulation 2016. PMID 27358432 · doi:10.1161/CIRCULATIONAHA.116.022335↩
  6. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010. PMID 21067804 · doi:10.1016/S0140-6736(10)61350-5↩
  7. Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019. PMID 30586774 · doi:10.1161/CIR.0000000000000625↩
  8. Dzaye O, et al. Warranty period of a calcium score of zero: comprehensive analysis from MESA. JACC Cardiovasc Imaging 2021. PMID 33129734 · doi:10.1016/j.jcmg.2020.06.048↩
  9. US Preventive Services Task Force; Curry SJ, et al. Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement. JAMA 2018. PMID 29998297 · doi:10.1001/jama.2018.8359↩
Book a Discovery Call Peptide Consult
Close
Book a Discovery Call
Close
Peptide Consult







    Transform Your
    Health & Wellness

    Fill up the form below to get started

      Provocation agent administered prior to timed urine collection (<6hr). Reveals toxic metal burden that can block hormone and peptide response.

      Identifies gluten sensitivity, intestinal permeability (leaky gut), and wheat-related immune reactivity – distinct from standard celiac testing.

      DNA Based stool test detecting pathogens, bacterial imbalances, parasites, and digestive markers – a comprehensive gut microbiome assessment.

      Non-invasive carotid artery ultrasound measuring arterial wall thickness – a direct look at your cardiovascular age.

      Cardio Res-Q cardiac risk panel – inflammation markers and cardiovascular biomarkers beyond standard labs.

      Evaluates intracellular vitamin, mineral, and antioxidant status – foundational to optimizing cellular health and peptide efficacy.

      Full Sex hormone, thyroid and adrenal picture. Identifies imbalances that affect energy, recovery, cognition, and peptide response.

      Advanced testing for immune reactions to wheat, gluten, and intestinal permeability.

      What It Evaluates

      Heavy metals like mercury, lead, cadmium, arsenic, and aluminum can cause:

      Conditions We Identify